Alimera Sciences Inc. (ALIM)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Alimera Sciences Inc. chart...

About the Company

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.

$108M

Total Revenue

487

Employees

$204M

Market Capitalization

-1.86

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ALIM News

Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript

19d ago, source: InvestingChannel on MSN

Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript March 7, 2024 Alimera Sciences, Inc. isn't one of the ...

Alimera Sciences Inc ALIM

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8d ago, source:

Each Inducement Grant was awarded as an inducement material to the employee’s commencement of employment in accordance with Nasdaq Listing Rule 5635 (c) (4), and each such Inducement Grant Each award ...

Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

9d ago, source:

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining ...

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

21d ago, source: Nasdaq

2022Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable ...

Alimera Sciences: Q4 Earnings Snapshot

21d ago, source: The Washington Post

ALPHARETTA, Ga. — ALPHARETTA, Ga. — Alimera Sciences Inc. (ALIM) on Thursday reported a loss of $3.8 million in its fourth quarter. The Alpharetta, Georgia-based company said it had a loss of ...

Alimera Sciences Inc ALIM

6d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript

20d ago, source: Seeking Alpha

Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Fourth Quarter and Fiscal Year 2023 Financial Results and Corporate Update Conference Call.

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

21d ago, source: Stockhouse

Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global ...

Q4 2023 Alimera Sciences Inc Earnings Call

20d ago, source: Yahoo Finance

Rick Eiswirth; President and Chief Executive Officer; Alimera Sciences Inc Elliot Maltz; Chief Financial Officer; Alimera Sciences Inc Scott Gordon; IR; CORE IR Alex Nowak; Analyst; Craig Hallum ...

Alimera Sciences Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Alimera Sciences, Inc.: Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

21d ago, source: Finanznachrichten

2022 Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...